Funding news
City Therapeutics logo

City Therapeutics Secures $99.5

Recently funded · $99.5M Series bHospitals and Health CareView source

Get the full City Therapeutics company profile

Access contacts, investors, buying signals & more

Open in Dashboard

The quest to unlock RNAi's full therapeutic potential just got a significant boost. City Therapeutics, a biotech firm founded by pioneering executives and scientists in the field, has secured $99.5M in Series B funding.

The company is focused on advancing next-generation engineering of small interfering RNAs (siRNAs) – the "trigger" molecules that mediate RNAi. This capital will fuel City Therapeutics' mission to improve and expand the reach of RNAi-based medicines, building a leading company in the space to help patients with a wide range of diseases.

Other recently funded companies

View all

Biggest recent Biotechnology rounds

Largest funding rounds in Biotechnology on Signalbase right now.

#CompanyAmount
1
Shockwave Medical logo

Shockwave Medical

United States

$13.1B
2
NeuroEM Therapeutics logo

NeuroEM Therapeutics

United States

$7.2B
3
Illumina logo

Illumina

United States

$7.1B
4
GRAIL logo

GRAIL

United States

$7.1B
5
RemeGen Biosciences logo

RemeGen Biosciences

United States

$5.6B

Other recent Series b rounds

Companies that recently closed a Series b round.

#CompanyAmount
1
Equal logo

Equal

India

$30.0M
2
ChAbS (Chinese Antibody Society) logo

ChAbS (Chinese Antibody Society)

United States

$101.0M
3
EqualAI logo

EqualAI

United States

$30.0M
4
PhoenixAI logo

PhoenixAI

United States

$80.0M
5
Coram AI logo

Coram AI

United States

$35.0M